SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway
Acta Biochimica et Biophysica Sinica · 2023
DOI: 10.3724/abbs.2023122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2023. Verfasst von Minghao Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Department of Infectious Diseases, the Third Afflicted Hospital of Wenzhou Medical University, Wenzhou 325200, China.
Zitieren
APA
Fan, M., Chen, Z., Shao, W., Chen, Y., Lin, Z., Yi, C., Li, Y., Lu, L., Zhou, Y., & Lin, J. (2023). SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2023122
Vancouver
Fan M, Chen Z, Shao W, Chen Y, Lin Z, Yi C, et al. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. Acta Biochimica et Biophysica Sinica. 2023. doi:10.3724/abbs.2023122
BibTeX
@article{Fan2023,
author = {Fan, Minghao and Chen, Zhenmei and Shao, Weiqing and Chen, Yiran and Lin, Zhifei and Yi, Chenhe and Li, Yitong and Lu, Lu and Zhou, Yu and Lin, Jing},
title = {SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2023},
doi = {10.3724/abbs.2023122}
}
EUVIMED